Lemborexant 5 mg
Sponsors
Eisai Inc., Nova Scotia Health Authority, Guangdong Provincial People's Hospital, University of British Columbia, Beijing Tiantan Hospital
Conditions
Cardiac SurgeryCardiac Surgery SubjectsDelirium - PostoperativeDementiaFeasibility StudiesFrontotemporal DementiaHealthy ParticipantsIn-hospital Mortality
Phase 1
Study to Evaluate the Effect of 2 Dosage Strengths of Lemborexant (E2006) on a Multiple Sleep Latency Test in Participants With Insomnia Disorder
CompletedNCT02350309
Start: 2014-12-13End: 2015-04-21Updated: 2020-01-18
Study to Evaluate the Effect of Lemborexant Versus Placebo on Driving Performance in Healthy Adult and Elderly Subjects
CompletedNCT02583451
Start: 2015-11-30End: 2017-02-28Updated: 2018-09-06
Phase 2
Study of Lemborexant for Irregular Sleep-Wake Rhythm Disorder and Mild to Moderate Alzheimer's Disease Dementia
CompletedNCT03001557
Start: 2016-12-20End: 2020-04-17Updated: 2021-05-17
Lemborexant to Prevent Post-operative Delirium in Cardiac Surgery Patients
Not yet recruitingNCT06648681
Start: 2025-05-01End: 2027-04-30Target: 60Updated: 2025-04-23
Lemborexant on Perioperative Sleep Quality in Patients Undergoing Thoracoscopic Surgery
Not yet recruitingNCT07811401
Start: 2026-10-08End: 2028-06-01Target: 130Updated: 2026-09-10